RxDoctor Payments Data

Bertram Johnson, MD

Cardiovascular Disease · Lancaster, PANPI 1477588218

Payments from drug & device makers

$2,710in general payments, 2019–2025

Across 142 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$807
  • Merck$429
  • Novo Nordisk$318
  • Esperion Therapeutics, Inc.$276
  • Amarin Pharma, Inc.$234
  • Amgen$165
  • plus $481 from 10 others

What the payments were for

  • Food & beverage$2,710100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,710 in reported general payments places this provider in the 55th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$4,037
Medicare patients
25
Services billed
61

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate13$14,983
EntrestoSacubitril/Valsartan16$13,045
XareltoRivaroxaban15$7,778
BrilintaTicagrelor11$5,456
Ranolazine ErRanolazine42$3,225
Valsartan43$2,081
Ezetimibe75$1,917
Nebivolol Hcl31$1,917
Atorvastatin Calcium83$982
Losartan Potassium42$489
Digoxin49$468
Potassium Chloride15$432
SotalolSotalol Hcl16$412
Rosuvastatin Calcium33$359
Verapamil ErVerapamil Hcl12$321

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$429$14,98313 claims
NovartisEntresto$807$13,04516 claims
Johnson & JohnsonXarelto$15$7,77815 claims
AstraZenecaBrilinta$56$5,45611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →